Skip to content
Screener

Alkermes ALKS Contingent Consideration Liability (Non-Current)

Contingent Consideration Liability (Non-Current) at other companies

Axsome Therapeutics logo
Axsome TherapeuticsAXSM
$73.73M-18.6%

Other financials

Income statement

See full
Revenue$496.0M+27.0%
Gross profit$397.9M+16.6%
Operating income$18.4M-80.3%
Net income$501.0K-99.4%
EPS (diluted)$0.00-100%

Balance sheet

See full
Cash & equivalents$511.5M-1.9%
Total debt$1.6B+2,064%
Total equity$1.8B+11.3%
Total assets$4.4B+95.0%

Cash flow

See full
Operating cash flow-$165.7M-268%
CapEx$8.1M-37.4%
Free cash flow-$169.8M-291%

Valuation

See full
Market cap$8.11B+85.1%
Enterprise value$9.18B+133%
P/E122.7×+110×
P/S4.9×+2.0×

Profitability

See full
Gross margin84.6%-0.6pp
Operating margin7%-17.8pp
Net margin4%-19.2pp
FCF margin14.2%-17.6pp

Returns & leverage

See full
Return on equity3.9%-20.1pp
Debt / equity0.9×+0.8×
Current ratio2.3×-0.9×

Where this comes from

Reported directly by Alkermes in its filing.

Tagged under the XBRL concept us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent.

The source filing: Alkermes’s 10-Q, filed July 28, 2026.

Filed
Jul 28, 2026, 9:22 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-319022
Line itemJune 30, 2026December 31, 2025
Current portion of long-term debt26,500—
Total current liabilities662,091543,437
OPERATING LEASE LIABILITIES—LONG-TERM61,97663,253
CONTINGENT CONSIDERATION136,304—
LONG-TERM DEBT1,476,611—
DEFERRED TAX LIABILITIES179,575—
OTHER LONG-TERM LIABILITIES68,01861,008
Total liabilities2,584,575667,698

Item 1. Condensed Consolidated Financial Statements:

FAQ

What is Alkermes's contingent consideration liability (non-current)?
Alkermes (ALKS) reported contingent consideration liability (non-current) of $136.3M in Q2 2026.

Ask your AI about Alkermes's contingent consideration liability (non-current).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude